The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials
Background: A large number of studies have demonstrated the effects of omega- 3 supplements containing mixtures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), known to favorably affect many modifiable risk factors of coronary heart disease (CHD). These studies have used diverse ratio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-03-01
|
| Series: | Complementary Therapies in Medicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0965229921000030 |
| _version_ | 1818643168475742208 |
|---|---|
| author | Suhad AbuMweis Deema Abu Omran Islam Al-Shami Stephanie Jew |
| author_facet | Suhad AbuMweis Deema Abu Omran Islam Al-Shami Stephanie Jew |
| author_sort | Suhad AbuMweis |
| collection | DOAJ |
| description | Background: A large number of studies have demonstrated the effects of omega- 3 supplements containing mixtures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), known to favorably affect many modifiable risk factors of coronary heart disease (CHD). These studies have used diverse ratios and doses of EPA and DHA. However, it is not known whether the ratio of EPA to DHA in omega-3 supplements affect their efficacy as modulators for cardiovascular risk factors. This meta-regression aimed to investigate the effect of different ratios of EPA to DHA on risk factors associated with CHD including lipid profile, blood pressure, heart rate, and inflammation. Method: A regression analysis was carried out on 92 clinical trials with acceptable quality (Jadad score ≥ 3) that were previously identified from two databases (PubMed and Cochrane Library). Results: Data from studies that met the inclusion criteria for this analysis showed that the ratio of EPA to DHA was not associated with lipid profile, diastolic blood pressure, or heart rate. With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (β = -1.3121 (95 % CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Using only studies that supplied EPA and DHA in the range of 2 g–6 g, the ratio of EPA to DHA was also associated with CRP (β = -2.10429 and 95 % CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Systolic blood pressure was only associated with an increasing EPA to DHA ratio in the 2 g–6 g range (β = 5.47129 and 95 % CI: 0.40677–10.53580), that is, a higher EPA to DHA ratio within this dose range, the greater the increase in SBP. Conclusion: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g–6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure. |
| first_indexed | 2024-12-16T23:54:40Z |
| format | Article |
| id | doaj.art-823d72f2572e45529f137fdb80663802 |
| institution | Directory Open Access Journal |
| issn | 0965-2299 |
| language | English |
| last_indexed | 2024-12-16T23:54:40Z |
| publishDate | 2021-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Complementary Therapies in Medicine |
| spelling | doaj.art-823d72f2572e45529f137fdb806638022022-12-21T22:11:14ZengElsevierComplementary Therapies in Medicine0965-22992021-03-0157102662The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trialsSuhad AbuMweis0Deema Abu Omran1Islam Al-Shami2Stephanie Jew3Department of Clinical Nutrition and Dietetics, Faculty of Applied Medical Sciences, The Hashemite University, P.O. Box 330127, Zarqa, 13133, Jordan; College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates; Corresponding author at: Department of Clinical Nutrition and Dietetics, Faculty of Applied Medical Sciences, the Hashemite University, P.O. Box 330127, Zarqa, 13133, Jordan.Independent Scholar, Amman, JordanDepartment of Clinical Nutrition and Dietetics, Faculty of Applied Medical Sciences, The Hashemite University, P.O. Box 330127, Zarqa, 13133, JordanIndependent Scholar, Ottawa, CanadaBackground: A large number of studies have demonstrated the effects of omega- 3 supplements containing mixtures of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), known to favorably affect many modifiable risk factors of coronary heart disease (CHD). These studies have used diverse ratios and doses of EPA and DHA. However, it is not known whether the ratio of EPA to DHA in omega-3 supplements affect their efficacy as modulators for cardiovascular risk factors. This meta-regression aimed to investigate the effect of different ratios of EPA to DHA on risk factors associated with CHD including lipid profile, blood pressure, heart rate, and inflammation. Method: A regression analysis was carried out on 92 clinical trials with acceptable quality (Jadad score ≥ 3) that were previously identified from two databases (PubMed and Cochrane Library). Results: Data from studies that met the inclusion criteria for this analysis showed that the ratio of EPA to DHA was not associated with lipid profile, diastolic blood pressure, or heart rate. With all studies, the ratio of EPA to DHA was associated with C-reactive protein (CRP) (β = -1.3121 (95 % CI: -1.6610 to -0.9543), that is, the higher the EPA to DHA ratio, the greater the reduction. Using only studies that supplied EPA and DHA in the range of 2 g–6 g, the ratio of EPA to DHA was also associated with CRP (β = -2.10429 and 95 % CI: -3.89963 to -0.30895); that is, an even more pronounced reduction in CRP with a higher EPA to DHA ratio. Systolic blood pressure was only associated with an increasing EPA to DHA ratio in the 2 g–6 g range (β = 5.47129 and 95 % CI: 0.40677–10.53580), that is, a higher EPA to DHA ratio within this dose range, the greater the increase in SBP. Conclusion: Current data suggest that the EPA to DHA ratio only correlates to the modulation of CRP by omega-3 supplementation of EPA and DHA, and SBP in studies that supplemented EPA and DHA in the range of 2 g–6 g, shedding light on potential differential effects of EPA vs. DHA on inflammation and systolic blood pressure.http://www.sciencedirect.com/science/article/pii/S0965229921000030Eicosapentaenoic acidDocosahexaenoic acidCoronary heart diseaseMeta-regression |
| spellingShingle | Suhad AbuMweis Deema Abu Omran Islam Al-Shami Stephanie Jew The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials Complementary Therapies in Medicine Eicosapentaenoic acid Docosahexaenoic acid Coronary heart disease Meta-regression |
| title | The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials |
| title_full | The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials |
| title_fullStr | The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials |
| title_full_unstemmed | The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials |
| title_short | The ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio-metabolic effects of omega-3 supplements: A meta-regression of randomized clinical trials |
| title_sort | ratio of eicosapentaenoic acid to docosahexaenoic acid as a modulator for the cardio metabolic effects of omega 3 supplements a meta regression of randomized clinical trials |
| topic | Eicosapentaenoic acid Docosahexaenoic acid Coronary heart disease Meta-regression |
| url | http://www.sciencedirect.com/science/article/pii/S0965229921000030 |
| work_keys_str_mv | AT suhadabumweis theratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT deemaabuomran theratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT islamalshami theratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT stephaniejew theratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT suhadabumweis ratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT deemaabuomran ratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT islamalshami ratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials AT stephaniejew ratioofeicosapentaenoicacidtodocosahexaenoicacidasamodulatorforthecardiometaboliceffectsofomega3supplementsametaregressionofrandomizedclinicaltrials |